Quarterly report pursuant to Section 13 or 15(d)

Note 10 - Shareholders' Equity

v3.20.2
Note 10 - Shareholders' Equity
6 Months Ended
Jun. 30, 2020
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]
1
0
.
Shareholders' Equity
 
Authorized capital stock
 
The Company has authorized share capital of an unlimited number of voting common shares and the shares do
not
have a stated par value.
 
Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to
one
vote per share at the Company's annual general meeting and any special meeting.
 
Equity issued
during
the
six
months ended
June 30, 2020
 
On
February 13, 2020,
we issued and sold an aggregate of
2,125,000
common shares in a public, underwritten offering at a public offering price of
$4.00
per share. As a result of the offering, we received gross proceeds of
$8.5
million, which resulted in net proceeds to us of approximately
$7.7
million, after deducting the underwriting discount and offering expenses.
 
During the
six
months ended
June 30, 2020,
7,200
common shares were issued on the exercise of options for gross proceeds of
$16,000
and
no
warrants were exercised.
 
Equity issued during the
six
months ended
June 30
,
2019
 
During the
six
months ended
June 30, 2019,
50,000
common shares were issued on the exercise of options for gross proceeds of
$75,000
and
no
warrants were exercised.
 
Shares reserved
 
Common shares reserved for future issuance are as follows:
 
   
June 30, 2020
 
Stock options outstanding
   
1,413,988
 
Deferred share units outstanding
   
47,237
 
Shares available for grant under the DiaMedica Therapeutics Inc. Omnibus Incentive Plan
   
1,103,551
 
Common shares issuable under common share purchase warrants
   
255,000
 
Total
   
2,819,776